在多发性骨髓瘤中,DOT1L抑制重新编程先天免疫力,以增强免疫调节药物反应的潜力

Kazuya Ishiguro1, Hiroshi Kitajima2, Takeshi Niinuma2

  • 1Division of Molecular Biology, Department of Biochemistry, Sapporo Medical University School of Medicine, Sapporo, Japan, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan, S1, W16, Chuo-ku, Sapporo, 060-8556, Japan; Department of Hematology, Tenshi hospital, Sapporo, Japan 1-1, N12, E3, Higashi-ku, Sapporo, 065-8611, Japan.

Cancer letters
|July 23, 2025
PubMed
概括

在多发性骨髓瘤 (MM) 中,DOT1L抑制通过激活先天性免疫反应并增强莱纳利多米德的疗效,显示出有前途. 这种表观遗传方法针对MM细胞的存活率,并提高了当前治疗的有效性.